Cigdem Selli

Cigdem Selli

Auto-generated profile, based on publicly available information

Cigdem Selli

Department of Pharmacology, Faculty of Pharmacy, Ege University, 35040, Izmir, Turkey.

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RMRuo-Yu Ma
Ruo-Yu Ma
HZHui Zhang
Hui Zhang
XLXue-Feng Li
Xue-Feng Li
CZCheng-Bin Zhang
Cheng-Bin Zhang
CSCigdem Selli
Cigdem Selli
BQBin-Zhi Qian
Bin-Zhi Qian
Bone metastasis is the major cause of death in breast cancer. The lack of effective treatment suggests that disease mechanisms are still largely unknown. As a key component of the tumor microenvironment, macrophages promote tumor progression and metastasis. In this study, we found that macrophages are abundant in human and mouse breast cancer bone metastases. Macrophage ablation significantly inhibited bone metastasis growth. Lineage tracking experiments indicated that these macrophages largely derive from Ly6C+CCR2+ inflammatory monocytes. Ablation of the chemokine receptor, CCR2, significantly inhibited bone metastasis outgrowth and prolonged survival. Immunophenotyping identified that bone metastasis–associated macrophages express high levels of CD204 and IL4R. Furthermore, monocyte/macrophage-restricted IL4R ablation significantly inhibited bone metastasis growth, and IL4R null mutant monocytes failed to promote bone metastasis outgrowth. Together, this study identified a subset of monocyte-derived macrophages that promote breast cancer bone metastasis in an IL4R-dependent manner. This suggests that IL4R and macrophage inhibition can have potential therapeutic benefit against breast cancer bone disease.

7 February 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
XLXue-Feng Li
Xue-Feng Li
CSCigdem Selli
Cigdem Selli
HZHan-Lin Zhou
Han-Lin Zhou
JCJian Cao
Jian Cao
SWShuiqing Wu
Shuiqing Wu
BQBin-Zhi Qian
Bin-Zhi Qian
Metastatic castration-resistant prostate cancer (PC) is the final stage of PC that acquires resistance to androgen deprivation therapies (ADT). Despite progresses in understanding of disease mechanisms, the specific contribution of the metastatic microenvironment to ADT resistance remains largely unknown. The current study identified that the macrophage is the major microenvironmental component of bone-metastatic PC in patients. Using a novel in vivo model, we demonstrated that macrophages were critical for enzalutamide resistance through induction of a wound-healing–like response of ECM–receptor gene expression. Mechanistically, macrophages drove resistance through cytokine activin A that induced fibronectin (FN1)-integrin alpha 5 (ITGA5)–tyrosine kinase Src (SRC) signaling cascade in PC cells. This novel mechanism was strongly supported by bioinformatics analysis of patient transcriptomics datasets. Furthermore, macrophage depletion or SRC inhibition using a novel specific inhibitor significantly inhibited resistant growth. Together, our findings elucidated a novel mechanism of macrophage-induced anti-androgen resistance of metastatic PC and a promising therapeutic approach to treat this deadly disease.

1 December 2016 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
CSCigdem Selli
Cigdem Selli
JDJ. Michael Dixon
J. Michael Dixon
ASAndrew H Sims
Andrew H Sims
Approximately 70% of patients have breast cancers that are oestrogen receptor alpha positive (ER+) and are therefore candidates for endocrine treatment. Many of these patients relapse in the years during or following completion of adjuvant endocrine therapy. Thus, many ER+ cancers have primary resistance or develop resistance to endocrine therapy during treatment. Recent improvements in our understanding of how tumours evolve during treatment with endocrine agents have identified both changes in gene expression and mutational profiles, in the primary cancer as well as in circulating tumour cells. Analysing these changes has the potential to improve the prediction of which specific patients will respond to endocrine treatment. Serially profiled biopsies during treatment in the neoadjuvant setting offer promise for accurate and early prediction of response to both current and novel drugs and allow investigation of mechanisms of resistance. In addition, recent advances in monitoring tumour evolution through non-invasive (liquid) sampling of circulating tumour cells and cell-free tumour DNA may provide a method to detect resistant clones and allow implementation of personalized treatments for metastatic breast cancer patients. This review summarises current and future biomarkers and signatures for predicting response to endocrine treatment, and discusses the potential for using approved drugs and novel agents to improve outcomes. Increased prediction accuracy is likely to require sequential sampling, utilising preoperative or neoadjuvant treatment and/or liquid biopsies and an improved understanding of both the dynamics and heterogeneity of breast cancer.

1 April 2015 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
CSCigdem Selli
Cigdem Selli
YEYasemin Eraç
Yasemin Eraç
BKBuket Kosova
Buket Kosova
EEEsra Erdal
Esra Erdal
MTMetiner Tosun
Metiner Tosun